{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:17Z","timestamp":1790270717931,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171341, 81771296"],"award-info":[{"award-number":["82171341, 81771296"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["2018SHZDZX01"],"award-info":[{"award-number":["2018SHZDZX01"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Recognizing the predictors of disease relapses in patients with anti-aquaporin-4 antibody (AQP4-ab)-positive neuromyelitis optica spectrum disorder (NMOSD) is essential for individualized treatment strategy. We aimed to identify the factors that predicted relapses among patients with AQP4-ab-positive NMOSD, develop outcome prediction models, and validate them in a multicenter validation cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Between January 2015 and December 2020, 820 patients with NMOSD were registered at Huashan Hospital. We retrospectively reviewed their medical records, and included 358 AQP4-ab-positive patients with 1135 treatment episodes. Univariate and multivariate analyses were used to explore the predictors of relapse, severe visual or motor disability during follow-up. A model predicting the 1- and 2-year relapse-free probability was developed and validated in an external validation cohort of 92 patients with 213 treatment episodes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Lower serum AQP4-ab titer (&amp;lt; 1:100), higher Expanded Disability Status Scale (EDSS) score at onset (\u2265 2.5), and use of intravenous methylprednisolone (IVMP) at the first attack predicted an overall lower annualized relapse rate. Older age (&amp;gt; 48 years), optic neuritis at onset, and higher onset EDSS score (\u2265 2.5) significantly increased the risk for blindness, while IVMP at the first attack and maintenance therapy reduced the risk for blindness. Myelitis at onset increased the possibility of motor disability (EDSS \u2265 6.0), severe motor disability or death (EDSS \u2265 8.0), while maintenance therapy reduced these possibilities. Anderson and Gill model identified that the risk factors predicting recurrent relapses under certain treatment status were female gender, high AQP4-ab titer (\u2265 1:100), previous attack under same therapy, lower EDSS score at treatment initiation (&amp;lt; 2.5), and no maintenance therapy or oral prednisone lasting less than 6 months. A nomogram using the above factors showed good discrimination and calibration abilities. The concordance indexes in the primary and validation cohort were 0.66 and 0.65, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study reports the demographic, clinical and therapeutic predictors of relapse, and severe visual or motor disability in NMOSD. Early identification of patients at risk of unfavorable outcomes is of paramount importance to inform treatment decisions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.873576","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T05:33:05Z","timestamp":1648704785000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models"],"prefix":"10.3389","volume":"13","author":[{"given":"Liang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzi","family":"ZhangBao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanzhen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis Optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(12)70133-3","article-title":"Aquaporin 4 and Neuromyelitis Optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of Neuromyelitis Optica: State-of-the-Art and Emerging Therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(20)30078-8","article-title":"Safety and Efficacy of Satralizumab Monotherapy in Neuromyelitis Optica Spectrum Disorder: A Randomised, Double-Blind, Multicentre, Placebo-Controlled Phase 3 Trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31817-3","article-title":"Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2\/3 Trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet (London England)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000009245","article-title":"Evaluation of Efficacy and Tolerability of First-Line Therapies in NMOSD","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s1474-4422(20)30066-1","article-title":"Safety and Efficacy of Rituximab in Neuromyelitis Optica Spectrum Disorders (RIN-1 Study): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in Neuromyelitis Optica Spectrum Disorder: Efficacy and Predictors of Response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic Factors and Disease Course in Aquaporin-4 Antibody-Positive Patients With Neuromyelitis Optica Spectrum Disorder From the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain: J Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516687403","article-title":"Predictors of Response to First-Line Immunosuppressive Therapy in Neuromyelitis Optica Spectrum Disorders","volume":"23","author":"Kim","year":"2017","journal-title":"Mult Scler (Houndmills Basingstoke England)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz054","article-title":"Outcome Prediction Models in AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain: J Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting Disease Patterns in Seropositive and Seronegative Neuromyelitis Optica: A Multicentre Study of 175 Patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflamm"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1212\/NXI.0000000000000004","article-title":"Predictors of Recurrence Following an Initial Episode of Transverse Myelitis","volume":"1","author":"Kimbrough","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000001729","article-title":"International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of Experimental Trials of Therapy in Multiple Sclerosis: Report by the Panel on the Evaluation of Experimentla Trials of Therapy in Multiple Sclerosis","volume":"122","author":"Schumacher","year":"1965","journal-title":"Ann N Y Acad Sci"},{"key":"B19","volume-title":"Rms: Regression Modeling Strategies","author":"Frank","year":"2021"},{"key":"B20","volume-title":"Survival","author":"Therneau","year":"2021"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06295361","article-title":"Decision Curve Analysis: A Novel Method for Evaluating Prediction Models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Mak"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu222","article-title":"Modelling Recurrent Events: A Tutorial for Analysis in Epidemiology","volume":"44","author":"Amorim","year":"2015","journal-title":"Int J Epidemiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.5984","article-title":"Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy","volume":"31","author":"Wang","year":"2013","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9128","article-title":"Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer","volume":"34","author":"Huang","year":"2016","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated Estimate of AQP4-IgG Serostatus and Disability Outcome in Neuromyelitis Optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101868","article-title":"Clinical and Therapeutic Predictors of Disease Outcomes in AQP4-IgG+ Neuromyelitis Optica Spectrum Disorder","volume":"38","author":"Kunchok","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082325","article-title":"Factors Associated With the Time to Next Attack in Neuromyelitis Optica: Accelerated Failure Time Models With Random Effects","volume":"8","author":"Kim","year":"2013","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical Spectrum and Prognostic Value of CNS MOG Autoimmunity in Adults: The MOGADOR Study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516685416","article-title":"Clinical Characteristics of Late-Onset Neuromyelitis Optica Spectrum Disorder: A Multicenter Retrospective Study in Korea","volume":"23","author":"Seok","year":"2017","journal-title":"Mult Scler (Houndmills Basingstoke England)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does Time Equal Vision in the Acute Treatment of a Cohort of AQP4 and MOG Optic Neuritis","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical Features and Risk of Relapse in Children and Adults With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in Oncology: More Than Meets the Eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.873576\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:52:01Z","timestamp":1648821121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.873576\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2022.873576"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.873576","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"article-number":"873576"}}